Get the Stockscreener App
8.255
1.91%
0.155
After Hours:
8.26
0.005
+0.06%
Anika Therapeutics Inc stock is traded at $8.255, with a volume of 309.41K.
It is up +1.91% in the last 24 hours and down -21.98% over the past month.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
See More
Previous Close:
$8.10
Open:
$8.1
24h Volume:
309.41K
Relative Volume:
3.14
Market Cap:
$118.39M
Revenue:
$166.88M
Net Income/Loss:
$-74.18M
P/E Ratio:
-1.6282
EPS:
-5.07
Net Cash Flow:
$1.14M
1W Performance:
-27.01%
1M Performance:
-21.98%
6M Performance:
-51.61%
1Y Performance:
-69.71%
1-Day Range:
$7.8701
$8.32
1-Week Range:
$7.8701
$11.61
52-Week Range:
$7.8701
$27.50
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
8.255 | 116.17M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | B. Riley Securities | Buy |
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc.ANIK - PR Newswire
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q2 2025 Earnings Call Transcript - Insider Monkey
Anika Therapeutics Inc (ANIK) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Why is Anika Therapeutics Inc. stock attracting strong analyst attentionPre Market Forecasts For Beginners - jammulinksnews.com
Anika Therapeutics 2025 Q2 Earnings Misses Targets as Net Loss Widens 4411.4% - AInvest
Anika Therapeutics Reports Q2 2025 Financial Results - TipRanks
Anika: Q2 Earnings Snapshot - Greenwich Time
Anika Therapeutics’ Earnings Call: A Mixed Outlook - TipRanks
Anika outlines 10%–20% commercial channel growth for 2026–2027 amid Hyalofast FDA timeline adjustment - MSN
Anika stock down on trial setback for cartilage repair product - Seeking Alpha
Anika Reports Topline Results from U.S. Pivotal FastTRACK - GlobeNewswire
Earnings call transcript: Anika Therapeutics Q2 2025 sees stock tumble despite revenue beat - Investing.com Australia
Anika Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Anika Therapeutics Q2 2025 slides: Revenue declines as OEM weakness persists By Investing.com - Investing.com South Africa
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Anika Therapeutics shares fall 8.87% premarket after Q2 revenue decline and Hyalofast trial miss. - AInvest
Anika Therapeutics Announces Phase III Study Results - TipRanks
Anika’s knee cartilage repair treatment misses primary endpoints By Investing.com - Investing.com India
Anika’s knee cartilage repair treatment misses primary endpoints - Investing.com
Anika Therapeutics Reports Second Quarter 2025 Financial Results - TradingView
Anika Reports Second Quarter 2025 Financial Results - GlobeNewswire
Anika Reports Mixed Q2 Results: Regenerative Solutions Soars 41% While Hyalofast Trial Misses Primary Endpoints - Stock Titan
Anika Reports Mixed Phase 3 Results: Hyalofast Shows Promise Despite Missing Primary Endpoints - Stock Titan
Combining machine learning predictions for Anika Therapeutics Inc.Pre-Market Stock Movement Summary and Review - Newser
Can Anika Therapeutics Inc. hit a new high this monthFree Risk Managed Intraday Trade Alerts - Newser
Why Anika Therapeutics Inc. stock attracts strong analyst attentionRisk Managed Intraday Trade Alerts Increase in Volume - metal.it
Anika Therapeutics Inc. Uptrend in Early Stages Indicators Say YesCapital Preserving Trade Plan Templates Shared - metal.it
Anika Therapeutics Inc (ANIK) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Anika Therapeutics Inc.’s volatility index tracking explainedFree Reversal Alert Based on RSI Indicator - Newser
Advanced analytics toolkit walkthrough for Anika Therapeutics Inc.Free Reversal Alert Based on RSI Indicator - Newser
What’s the recovery path for long term holders of Anika Therapeutics Inc.Day Trading Plan with Entry Risk Management - Newser
Why Anika Therapeutics Inc. stock is on top investor watchlistsWeekly Growth Portfolio Performance Summary - Newser
Published on: 2025-07-29 10:40:40 - metal.it
Custom strategy builders for tracking Anika Therapeutics Inc.Free Short Term Buy List With Stop Protection - Newser
Technical analysis overview for Anika Therapeutics Inc. stockFree High Accuracy Alerts for ROI Traders - Newser
How did ANIK's Q4 earnings surprise impact investor sentiment? - AInvest
RSI Divergence May Trigger a Bounce in Anika Therapeutics Inc.Short Term Trading Opportunity Watch Sees Shift - metal.it
What are the latest earnings results for Anika Therapeutics Inc.AI Powered Planner Backed By Experts - jammulinksnews.com
Should I hold or sell Anika Therapeutics Inc. stock in 2025Earnings Report Alerts For Every Investor - jammulinksnews.com
Technical analysis overview for Anika Therapeutics Inc. stock Breakout Watcher with Entry and Exit Alerts - Newser
Combining machine learning predictions for Anika Therapeutics Inc. Smart Forecast Signals from AI Models - Newser
What makes Anika Therapeutics Inc. stock price move sharplyCapitalize on stocks with high profit margins - jammulinksnews.com
How does Anika Therapeutics Inc. compare to its industry peersDaily Trading Strategy To Watch Now - jammulinksnews.com
How strong is Anika Therapeutics Inc. company’s balance sheetOutstanding risk-reward balance - jammulinksnews.com
How Anika Therapeutics Inc. stock performs during market volatilityStable Growth Stock Picks - metal.it
Is Anika Therapeutics Inc. a growth stock or a value stockRapid wealth accumulation - jammulinksnews.com
Published on: 2025-07-28 03:48:38 - jammulinksnews.com
What institutional investors are buying Anika Therapeutics Inc. stockFree Market Volatility Navigation Tips - jammulinksnews.com
When is Anika Therapeutics Inc. stock expected to show significant growthRobust financial gains - jammulinksnews.com
Cerity Partners LLC Takes Position in Anika Therapeutics Inc. (NASDAQ:ANIK) - Defense World
What analysts say about Anika Therapeutics Inc. stockExplosive trading opportunities - PrintWeekIndia
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):